英国免疫抑制人群接种三剂及以上COVID-19疫苗后的抗体阳性率:MELODY横断面研究
该研究利用英国国家疾病注册系统开展横断面研究,招募实体器官移植受者、罕见自身免疫性风湿病患者和淋系恶性肿瘤患者,共23036人提供血清学数据。结果显示,尽管接种三剂及以上COVID-19疫苗,实体器官移植受者中23.3%、罕见自身免疫性风湿病患者中14.1%、淋系恶性肿瘤患者中20.7%检测不到IgG抗刺突抗体,且抗体阳性率随加强针次增加而升高,免疫抑制剂种类与血清学应答强烈相关。
要点
- 实体器官移植受者中23.3%检测不到IgG抗刺突抗体,罕见自身免疫性风湿病患者中为14.1%,淋系恶性肿瘤患者中为20.7%。
- 所有组别中,抗体阳性与较年轻年龄、较高疫苗剂次(即五剂对比三剂)及既往COVID-19感染相关。
- 接受抗增殖药、钙调神经磷酸酶抑制剂和类固醇联合治疗的实体器官移植受者,以及接受抗CD20治疗的罕见自身免疫性风湿病或淋系恶性肿瘤患者,抗体阳性比值最低。
核心结论
- 约五分之一的实体器官移植受者、罕见自身免疫性风湿病患者和淋系恶性肿瘤患者尽管接种三剂及以上疫苗,仍检测不到IgG抗刺突抗体,但该比例随序贯加强针次增加而降低。
- 免疫抑制剂选择和疾病类型与血清学应答强烈相关。
- 使用侧流免疫分析进行抗体检测可能有助于快速识别最可能从额外COVID-19干预中获益的个体。
研究设计与样本
- 横断面研究,利用英国国家疾病注册系统识别、联系并招募实体器官移植受者、罕见自身免疫性风湿病患者和淋系恶性肿瘤患者,要求年满18岁、居住在英国且已接种至少三剂COVID-19疫苗。
- 招募开放期为2021年12月7日至2022年6月26日;参与者在家庭环境下完成SARS-CoV-2刺突抗体侧流免疫分析检测并填写在线问卷。
- 采用多变量逻辑回归估计各特征与抗体阳性的互调比值比;共筛查101972人(邀请98725人,自行入组3247人),招募28411人(27.9%),其中23036人(81.1%)提供血清学数据。
主要发现
- 23036名有血清学数据的参与者中,实体器官移植受者9927人(43.1%),罕见自身免疫性风湿病患者6516人(28.3%),淋系恶性肿瘤患者6593人(28.6%);男性10485人(45.5%),女性12535人(54.4%),性别未报告16人(<0.1%),白人21661人(94.0%)。
- 实体器官移植受者中位年龄60岁(SD 50-67),罕见自身免疫性风湿病患者65岁(54-73),淋系恶性肿瘤患者69岁(61-75)。
- 23036名有血清学数据的参与者中,接种三剂疫苗6583人(28.6%),四剂14234人(61.8%),五剂及以上2219人(9.6%)。
- IgG抗刺突抗体检测不到的比例:实体器官移植受者9927人中2310人(23.3%),罕见自身免疫性风湿病患者6516人中922人(14.1%),淋系恶性肿瘤患者6593人中1366人(20.7%)。
- 所有组别中抗体阳性与较年轻年龄、较高疫苗剂次(即五剂对比三剂)及既往COVID-19感染相关;接受抗增殖药、钙调神经磷酸酶抑制剂和类固醇联合治疗的实体器官移植受者,以及接受抗CD20治疗的罕见自身免疫性风湿病或淋系恶性肿瘤患者,抗体阳性比值最低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the UK, additional COVID-19 vaccine booster doses and treatments are offered to people who are immunosuppressed to protect against severe COVID-19, but how best to choose the individuals that receive these vaccine booster doses and treatments is unclear. We investigated the association between seropositivity to SARS-CoV-2 spike protein with demographic, disease, and treatment-related characteristics after at least three COVID-19 vaccines in three cohorts of people who are immunosuppressed. METHODS: In a cross-sectional study using UK national disease registries, we identified, contacted, and recruited recipients of solid organ transplants, participants with rare autoimmune rheumatic diseases, and participants with lymphoid malignancies who were 18 years or older, resident in the UK, and who had received at least three doses of a COVID-19 vaccine. The study was open to recruitment from Dec 7, 2021, to June 26, 2022. Participants received a lateral flow immunoassay test for SARS-CoV-2 spike antibodies to complete at home, and an online questionnaire. Multivariable logistic regression was used to estimate the mutually adjusted odds of seropositivity against each characteristic. FINDINGS: Between Feb 14 and June 26, 2022, we screened 101 972 people (98 725 invited, 3247 self-enrolled) and recruited 28 411 (27·9%) to the study. 23 036 (81·1%) recruited individuals provided serological data. Of these, 9927 (43·1%) were recipients of solid organ transplants, 6516 (28·3%) had rare autoimmune rheumatic diseases, and 6593 (28·6%) had lymphoid malignancies. 10 485 (45·5%) participants were men and 12 535 (54·4%) were women (gender was not reported for 16 [<0·1%] participants), and 21661 (94·0%) participants were of White ethnicity. The median age of participants with solid organ transplants was 60 years (SD 50-67), with rare autoimmune rheumatic diseases was 65 years (54-73), and with lymphoid malignancy was 69 years (61-75). Of the 23 036 participants with serological data, 6583 (28·6%) had received three vaccine doses, 14 234 (61·8%) had received four vaccine doses, and 2219 (9·6%) had received five or more vaccine doses. IgG anti-spike antibodies were undetectable in 2310 (23·3%) of 9927 patients with solid organ transplants, 922 (14·1%) of 6516 patients with rare autoimmune rheumatic diseases, and 1366 (20·7%) of 6593 patients with lymphoid malignancies. In all groups, seropositivity was associated with younger age, higher number of vaccine doses (ie, five vs three), and previous COVID-19. Immunosuppressive medication reduced the likelihood of seropositivity: the lowest odds of seropositivity were found in recipients of solid organ transplants receiving a combination of an anti-proliferative agent, a calcineurin inhibitor, and steroids, and those with rare autoimmune rheumatic diseases or lymphoid malignancies treated with anti-CD20 therapies. INTERPRETATION: Approximately one in five recipients of solid organ transplants, individuals with rare autoimmune rheumatic diseases, and individuals with lymphoid malignancies have no detectable IgG anti-spike antibodies despite three or more vaccine doses, but this proportion decreases with sequential booster doses. Choice of immunosuppressant and disease type is strongly associated with serological response. Antibody testing using lateral flow immunoassay tests could enable rapid identification of individuals who are most likely to benefit from additional COVID-19 interventions. FUNDING: UK Research and Innovation, Kidney Research UK, Blood Cancer UK, Vasculitis UK and the Cystic Fibrosis Trust.
引用
- Pearce FA, Lim SH, Bythell M, et al. Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY. Lancet Rheumatol. 2023. PMID: 38251578. doi:10.1016/S2665-9913(23)00160-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。